GSK reported solid Q2 and first half 2026 results, with core turnover and earnings per share growth hitting the high end of guidance. Despite meeting its long-term sales targets, the stock's forward price-to-earnings ratio and dividend yield offer limited investment appeal. Analysts see only modest potential for price gains, making it difficult to recommend buying the stock at this time. Investors seeking growth opportunities may need to look beyond GSK for better returns.
The FTSE 100 index rose 98 points to 10,880, nearing its all-time high, driven by strong quarterly results from Unilever, which posted its best volume growth in over ten years. Other notable gainers included GSK, Diageo, and Croda, buoyed by positive...
GSK's shares rose to a three-month high after the company reported better-than-expected second-quarter results, with revenue up 5% to £8.41 billion and adjusted earnings per share increasing 9% to 50.5p. Vaccine sales grew 8%, notably with Shingrix a...
